Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases

Abstract excerpt

Complement therapeutics have been increasingly tested and approved for human diseases, often in orphan diseases with strong and apparently causal genetic linkage or mutation-associated features. However, the complement system has been demonstrated to be activated in essentially all human inflammatory, ischemic and autoimmune diseases, suggesting the possibility of even wider therapeutic applications. The goal of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Complement system in diseases
• Share to Renal Diseases and Glomerulopathies
• Share to Systemic Lupus Erythematosus Research